Andrew Seidman, MD: Efficacy Data Supporting the Use of Eribulin Mesylate

What efficacy data support the use of eribulin mesylate in this patient with metastatic TNBC?

The EMBRACE trial was a prospective, randomized study of over 700 women and the treatment recommendation really reflected the real-world care of women. Either your received Halaven or you received treatment of a physician's choice, which was left up to the discretion of the physician, who could choose what they thought that patient would benefit most from. This is based on her comorbidities, based on what she had received previously, and given that choice, eribulin was superior.

Triple Negative Breast Cancer: Case 1

Christine H is a 54-year-old stay-at-home-mother who works part time as a real estate agent. Medical history is notable for hypertension (well controlled) and surgery for aortic aneurysm in 2011

In September 2013, she presented to her PCP with a right breast lump; mammogram showed a large primary breast mass and two enlarged axillary lymph nodes.

• She underwent an extent of disease evaluation, which consisted of a chest, abdomen, pelvis, and bone scan, which showed no evidence of distant metastases
• Ultrasound-guided core needle biopsy of the right breast mass revealed grade 3 invasive ductal carcinoma that was ER-, PgR-, and HER2- (triple-negative) with cytokeratin 5/6 staining and 50% Ki67 staining
• The patient proceeded to right breast mastectomy and axillary lymph node dissection in October 2013
• She had a 4.8cm invasive breast cancer and the axillary lymph node dissection showed 15 positive nodes
• She underwent adjuvant therapy with doxorubicin plus cyclophosphamide (4 cycles), followed up by paclitaxel (4 cycles) and post-mastectomy radiation

At her follow-up in May 2014, the patient showed progression of the right chest wall metastases, and several new liver lesions were detected.

• She underwent therapy with paclitaxel plus bevacizumab for 5 cycles and her disease stabilized

In December of 2014, she presented with increasing fatigue and chest pain on follow up and her CT scan was consistent with progression of the hepatic metastases, with several new lesions also noted in the lungs; her ECOG performance status (PS) at the time was 1.

• She underwent therapy with pegylated liposomal doxorubicin and had a partial response after 4 cycles of therapy. After 6 cycles of therapy, she experienced progression
• Her CBC, liver, and kidney function at the time of progression were within normal limits
• Her oncologist initiated therapy with eribulin mesylate (1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle)
• She experienced a partial response. Dose was reduced to 1.1 mg/m2 after she developed grade 3 peripheral neuropathy
• Her condition improved at the reduced dose and she continues in remission after 4 cycles